International Stem Cell director disposes of 30K options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
International Stem Cell CORP (ISCO) reported that director Paul V. Maier disposed of stock options to the issuer on September 16, 2026. The transaction covered 30,000 stock options exercisable at $0.12 per share for common stock and left him with no remaining options of this grant. The options, originally granted on June 11, 2024, had fully vested on June 11, 2025, and were scheduled to expire on June 11, 2034. No Rule 10b5-1 trading plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Options F1 | 30,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. The shares subject to the option fully vested on 06/11/2025 from the date of grant (06-11-2024).
Key Figures
Key Terms
Stock Options financial
Disposition to issuer financial
Exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ISCO disclose for Paul V. Maier?
How many ISCO stock options were involved in Paul V. Maier’s Form 4?
What was the exercise price of the ISCO options disposed of by Paul V. Maier?
Does Paul V. Maier still hold any ISCO options from this grant after the transaction?
Were Paul V. Maier’s ISCO option transactions made under a Rule 10b5-1 plan?
When did the ISCO options disposed by Paul V. Maier vest and when would they have expired?
AI-generated analysis. How Rhea-AI works. Not financial advice.